Rozlytrek is indicated for treating NTRK fusion-positive solid tumours and
ROS1-positive advanced or metastatic non-small cell lung cancer.1,2

Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing an NTRK gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options.3

Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors.3








Click here to access Rozlytrek patient materials

Click here to email your local Conditions Partner for more information

Click here  to access the dosage information page 

References:

  1. https://www.nice.org.uk/guidance/TA644 last accessed August 2020
  2. https://www.nice.org.uk/guidance/ta643 last accessed August 2020
  3. ROZLYTREK Summary of Product Characteristics available at: www.medicines.org.uk/emc

Abbreviations

NTRK: neurotrophic tyrosine receptor kinase

NSCLC: non-small cell lung cancer

Reporting Adverse Events

▼ ROZLYTREK is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.


M-GB-00002179

November 2020